The Homeopathic Antiarthitic Preparation Zeel comp. N: A Review of Molecular and Clinical Data

Explore: The Journal of Science and Healing

Volumn 3, Issue 1, 2007, Pages 16-22

  Birnesser, Heinz ^a   Stolt, Pelle ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Maglia Rotta   (Switzerland)

Author keywords

Arthritis; cyclooxygenases; homeopathy; leukotrienes; prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; AMENTOFLAVONE; ANTIRHEUMATIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARNICA MONTANA EXTRACT; BIOFLAVONOID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HERBACEOUS AGENT; HYALURONIC ACID; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; LEUKOTRIENE DERIVATIVE; LICOFELONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN; RHUS GLABRA EXTRACT; ROFECOXIB; SANGUINARIA CANADENSIS EXTRACT; SOLANUM DULCAMARA EXTRACT; SULFUR; THROMBOXANE; TOXICODENDRON QUERCIFOLIUM EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZEEL;

ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; ASTHMA; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HOMEOPATHY; HUMAN; IN VITRO STUDY; INFLAMMATION; OSTEOARTHRITIS; PAIN; POISON IVY; PRIORITY JOURNAL; SANGUINARIA; SANGUINARIA CANADENSIS; SOLANUM; SOLANUM DULCAMARA; STRUCTURE ANALYSIS; TOXICODENDRON QUERCIFOLIUM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HOMEOPATHY; HUMANS; META-ANALYSIS; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS; SULFUR COMPOUNDS;

EID: 33846166415     PISSN: 15508307     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.explore.2006.10.002     Document Type: Article

References (53)

1. Homöopathisches Arzneibuch 2000 (German Homeopathic Pharmacopoeia). Stuttgart: Medpharm GmbH Scientific Publishers, 2003.
2. Martel-Pelletier J., Lajeunesse D., Reboul P., and Pelletier J.P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 62 (2003) 501-509
3. Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one?. J Rheumatol 28 (2001) 2375-2382
4. Brune K. Safety of anti-inflammatory treatment-new ways of thinking. Rheumatology 43 (2004) i16-i20
5. Raisz L.G. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 7 (1999) 419-421
6. Hudson N., Balsitis M., Everitt S., and Hawkey C. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal antiinflammatory drugs. Gut 34 (1993) 742-747
7. Bisgaard H. Leukotrienes and prostaglandins in asthma. Allergy 39 (1984) 413-420
8. Fiorucci S., Meli R., Bucci M., and Cirino G. Dual inhibitors of cyclo-oxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?. Biochem Pharmacol 62 (2001) 1433-1438
9. Laufer S., Tries S., Agustin J., and Dannhardt G. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforsch 44 (1994) 629-636
10. Celotti F., and Durand T. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins Other Lipid Mediat 71 (2003) 147-162
11. Tramer M.R., Moore R.A., Reynolds D.J., and McQuay H.J. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85 (2000) 169-182
12. Singh G., and Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 56 (1999) 18-24
13. Safety concerns associated with over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use: 2004. Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/drug/analgesics/SciencePaper.pdf. Accessed August 15, 2006.
14. Lyss G., Schmidt T.J., Merfort I., and Pahl H.L. Helenalin, an antiinflammatory sesquiterpene lactone from Arnica selectively inhibits transcription factor NF-kappaB. Biol Chem 378 (1997) 951-961
15. Klaas C.A., Wagner G., Laufer S., et al. Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica Flowers. Planta Med 68 (2002) 385-391
16. Godowski K.C. Antimicrobial action of sanguinarine. J Clin Dent 1 (1998) 96-101
17. Kurokawa M., Basnet P., Oshugi M., Hozumi T., Kadota S., and Namba T. Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica in vitro and in vivo. J Pharmacol Exp Ther 289 (1999) 72-78
18. Lin Y.M., Anderson H., Flavin M.T., Pai Y.H., Mata-Greenwood E., and Pengsuparp T. In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod 60 (1997) 884-888
19. Saxena G., McCutcheon A.R., Farmer S., Towers G.H., and Hancock R.E. Antimicrobial constituents of Rhus glabra. J Ethnophamacol 42 (1994) 95-99
20. Tunon H., Olavsdotter C., and Bohlin L. Evaluation of anti-inflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. J Ethnopharmacol 48 (1995) 61-76
21. Tunon H., Olavsdotter C., and Bohlin L. Evaluation of antiinflammatory activity of some Swedish medicinal plants. Inhibition of prostaglandin biosynthesis and PAF-induced exocytosis. J Ethnopharmacol 48 (1995) 61-76
22. Kurz B., Lemke A.K., Fay J., Pufe T., Grodzinsky A.J., and Schunke M. Pathomechanisms of cartilage destruction by mechanical injury. Ann Anat 187 (2005) 473-485
23. Yamada H., Watanabe K., Saito T., et al. Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol 26 (1999) 654-662
24. Johnson L.L., Dyer R., and Hupe D.J. Matrix metalloproteinases. Curr Opin Chem Biol 2 (1998) 466-471
25. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., and Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21 (1998) 75-80
26. Coussens L.M., and Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 3 (1996) 895-904
27. In: Hawkes S.P., Edwards D.R., and Khokha R. (Eds). Inhibitors of Metalloproteinases in Development and Disease (1997), Harwood, Lausanne, Switzerland
28. Jaggi R., Wurgler U., Grandjean F., and Weiser M. Dual inhibition of 5-lipoxygenase/cyclooxygenase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability. Inflamm Res 53 (2004) 150-157
29. Blasey H.D., Lundstrom K., Tate S., and Bernard A.R. Recombinant protein production using the Semliki Forest Virus expression. Cytotechnol 24 (1997) 65-72
30. Bennett C.F., Chiang M.Y., Monia B.P., and Crooke S.T. Regulation of 5-lipoxygenase and 5-lipoxygenase-activating protein expression in HL-60 cells. Biochem J 289 (1993) 33-39
31. Werz O., Schneider N., Brungs M., Sailer E.R., Safayhi H., and Ammon H.P.T. A test system for leukotriene synthesis inhibitors based on the in vitro differentiation of human leukemic cell lines HL-60 and Mono Mac 6. Naunyn-Schmiedebergs Arch Pharmacol 356 (1997) 441-445
32. Nahler G., Metelmann H., and Sperber H. Treatment of gonartrosis with Zeel-results of a randomised, comparative clinical trial with hyaluronic acid. Orthopädische Praxis 32 (1996) 354-359
33. Maronna U., Weiser M., and Klein P. Oral treatment of gonarthritis with Zeel-results of a double-blind equivalence study versus Diclofenac. Orthopaedische Praxis 36 (2000) 285-291
34. Altman R., Asch E., and Bloch D. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 29 (1986) 1039-1049
35. Kellgren J.H., and Lawrence J.S. Radiological assessment of osteoarthritis. Ann Rheum Dis 16 (1957) 494-501
36. Lequesne M. Klinische und röntgenologische Verlaufsbeobachtung bei Hüft und Kniearthrosen-Methoden und Ergebnisse. Z Rheumatol (1994) 243-249
37. Stucki G., Meier D., and Stucki S. Evaluation einer deutschen version des WOMAC-Arthroseindex [Evaluation of a German version of the WOMAC Arthrosis Index]. Z Rheumatol 55 (1996) 40-49
38. Birnesser H., Klein H.-P., and Weiser M. A modern homeopathic medication works as well as COX 2 inhibitors. Der Allgemeinarzt 25 (2003) 261-264
39. Richter M. Arthrose (1983), PVG Pharmazeutische Verlagsgesellschaft mbH, Munich, Germany
40. Zenner S., and Metelmann H. Praxiserfahrungen mit einem Homöopathischen Zäpfchenpräparat. Therapeuticon 5 (1991) 63-68
41. Müller-Krampe B., Gottwald R., and Weiser M. Symtomatische behandlung von akuten fieberhaften infekten mit einem modernen homöopathikum [Symptomatic treatment of acute febrile infections with a modern homeopathic preparation]. Biol Med 31 (2002) 79-85
42. Ong K.S., and Seymour R.A. Pain measurement in humans. Surgeon 2 (2004) 15-27
43. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 312 (1996) 1215-1218
44. Derasse M., Klein H., and Weiser M. The effects of homeopathic preparation Viburcol compared with acetaminophen in the symptomatic treatment of acute febrile infections in children: an observational pilot study. Explore (NY) 1 (2005) 33-39
45. Feder G., and Katz T. Randomised controlled trials for homoeopathy. BMJ 324 (2002) 498-499
46. Dollery C.M., Owen C.A., Sukhova G.K., Krettek A., Shapiro S.D., and Libby P. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation 107 (2003) 2829-2836
47. Seyama Y., and Wachi H. Atherosclerosis and matrix dystrophy. J Atheroscler Thromb 11 (2004) 236-245
48. Katayama K., and Fujita T. Studies on biotransformation of elastase. III. Effects of elastase binding proteins in serum on the disappearance of 131 I-labeled elastase from blood. Biochim Biophys Acta 336 (1974) 165-177
49. Rao J.K., Mihaliak K., Kroenke K., Bradley J., Tierney W.M., and Weinberger M. Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med 131 (1999) 409-416
50. Vecchio P.C. Attitudes to alternative medicine by rheumatology outpatient attenders. J Rheumatol 21 (1994) 145-147
51. Pioro-Boisset M., Esdaile J.M., and Fitzcharles M.A. Alternative medicine use in fibromyalgia syndrome. Arthritis Care Res 9 (1996) 13-17
52. Arcury T.A., Bernard S.L., Jordan J.M., and Cook H.L. Gender and ethnic differences in alternative and conventional arthritis remedy use among community-dwelling rural adults with arthritis. Arthritis Care Res 9 (1996) 384-390
53. Nicassio P.M., Schuman C., Kim J., Cordova A., and Weisman M.H. Psychosocial factors associated with complementary treatment use in fibromyalgia. J Rheumatol 24 (1997) 2008-2013